TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07923747: A Two-part, First-In-Human, Phase I, Open-label, Ascending Dose Study to Assess Safety and Tolerability of DKB903 in Participants With Rheumatoid Arthritis (RA) and Participants With Systemic Lupus Erythematosus (SLE)

Sponsor: Novartis Pharmaceuticals · Phase: PHASE1 · Area: IMMUNOLOGY · Target Enrollment: 90 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,507,200

Rescue Site Savings

+$4,950,060

Unlock Full NCT07923747 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07923747 Rescue Dossier →